Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed has announced the granting of inducement awards to nine new employees as part of their recruitment strategy, compliant with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 42,320 shares at an exercise price of $33.25, the closing price on October 1, 2020. The options come with a ten-year term and a four-year vesting schedule, designed to retain talent in a competitive industry. Insmed focuses on advancing therapies for serious and rare diseases, including ARIKAYCE, brensocatib, and treprostinil palmitil.
Insmed Incorporated (Nasdaq: INSM) announced progress at its virtual R&D Day, highlighting its expanding portfolio aimed at treating serious and rare diseases. The company initiated a Phase 1 trial for Treprostinil Palmitil Inhalation Powder (TPIP) and plans to begin a Phase 2a study for pulmonary arterial hypertension in early 2021. Insmed aims to leverage its drug brensocatib to address neutrophil-mediated diseases, starting with a Phase 3 trial for non-cystic fibrosis bronchiectasis. The company also detailed global expansion efforts for its product ARIKAYCE, expecting EU marketing authorization by October 2020.
Insmed, a biopharmaceutical company, will host a virtual R&D Day on September 30, 2020, from 10:00 a.m. to 12:30 p.m. ET. The event will highlight updates on pipeline candidates, including treprostinil palmitil and brensocatib, as well as advancements for ARIKAYCE (amikacin liposome inhalation suspension). Dr. Ronald J. Oudiz will present during the event. The conference call will be accessible live and recorded for later viewing. Insmed focuses on serious and rare diseases with its innovative therapies.
Insmed Incorporated (Nasdaq:INSM) announced participation in three virtual investor conferences in September 2020. Management will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, Morgan Stanley Annual Global Healthcare Conference on September 15, 2020, and the Cantor Virtual Healthcare Conference on September 17, 2020. Each presentation will be streamed live, accessible on the company's investor relations webpage and archived for 30 days. Insmed focuses on treatments for serious rare diseases, including its product ARIKAYCE®.
Insmed announced the publication of final results from the Phase 2 WILLOW study for brensocatib, a treatment for non-cystic fibrosis bronchiectasis (NCFBE), in the New England Journal of Medicine. Findings showed significant improvement in time to first pulmonary exacerbation compared to placebo, with risk reductions of 42% and 38% for two dosages. The treatment was well tolerated, with manageable adverse events. Insmed aims to initiate a Phase 3 program for brensocatib by year-end 2020, highlighting the urgency for therapeutic options in NCFBE.
Insmed Incorporated (Nasdaq: INSM) announced the grant of inducement awards to 12 new employees as per NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, these awards include options to purchase a total of 84,520 shares at an exercise price of $28.17 per share, which is the closing price on September 1, 2020. The options come with a ten-year term and a four-year vesting schedule, aimed at incentivizing employee retention and commitment to the company.
Insmed Incorporated (Nasdaq: INSM) has granted inducement awards to 11 new employees, in compliance with NASDAQ Listing Rule 5635(c)(4). These awards, approved by the Compensation Committee, consist of options to purchase a total of 76,960 shares of Insmed common stock at an exercise price of $27.15 per share, based on the closing price on August 3, 2020. The options are valid for a ten-year term and will vest over four years, promoting employee retention and commitment to the company.
Insmed reported strong Q2 2020 results, achieving $42.5 million in total revenue, up from $30.0 million in Q2 2019. U.S. sales of ARIKAYCE reached $41.0 million, reflecting growth amidst COVID-19 challenges. The company also reported a net loss of $61.9 million or $0.64 per share, improving from a $66.5 million loss in the prior year. Notably, brensocatib received FDA Breakthrough Therapy Designation, and ARIKAYCE gained a positive opinion from the CHMP for treating NTM lung infections, signaling potential market expansion.
Insmed Incorporated (NASDAQ: INSM) will announce its second quarter 2020 financial results on August 6, 2020. A conference call for investors is scheduled for 8:30 a.m. ET on the same day, aimed at discussing the financial outcomes and offering a business update. Interested parties can join by calling (888) 317-6003 for domestic or (412) 317-6061 for international access, referencing conference ID 9359069. The call will also be available via live webcast on Insmed's official website.
Insmed has received a positive opinion from the CHMP for ARIKAYCE Liposomal 590 mg, aimed at treating non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in adults with limited treatment options. A final decision from the European Commission is expected in the second half of 2020. This recommendation follows promising results from the Phase 3 CONVERT study, showing improved sputum culture conversion rates when ARIKAYCE is used with a multi-drug regimen. If approved, ARIKAYCE would be the first approved therapy for this condition in both Europe and the United States.